Last Price$146.6(0.1%)
Market Cap$9,757.8M
LTM Cash & Cash Equivalents
$223.8M
YoY Growth
+0.1%
3Y CAGR
+22.1%
5Y CAGR
-1.5%
Stock quality & Intrinsic value
7/10
19.0% undervalued
AptarGroup, Inc. Cash & Cash Equivalents
Annual
Quarterly
LTM
Crunching data... Almost there!
| Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Cash Equivalents | $117.6M | $170.6M | $313.7M | $192.1M | $333.0M | $376.4M | $377.6M | $229.8M | $309.9M | $399.8M | $489.9M | $466.3M | $714.4M | $261.8M | $242.0M | $300.1M | $122.9M | $141.7M | $223.6M | $223.8M |
Overvalued or undervalued?
Check the intrinsic value for ATR
and see if it's the right time to invest.
AptarGroup, Inc. (ATR) Cash & Cash Equivalents comparison analysis
General
LTM Cash & Cash Equivalents
Growth
Company name
YoY growth
3Y CAGR
5Y CAGR
AptarGroup, Inc.ATR
$223.8M
0.1%
22.1%
(1.5%)
Median Peer Set
$747.5M
(18.6%)
4.5%
6.9%
Intuitive Surgical, Inc.ISRG
$2,027.4M
(26.3%)
16.2%
11.7%
Alcon Inc.ALC
$1,829.0M
67.2%
5.1%
17.3%
Hologic, Inc.HOLX
$1,782.1M
(7.8%)
7.8%
36.9%
Baxter International Inc.BAX
$1,764.0M
(44.8%)
(15.8%)
(12.0%)
Repligen CorporationRGEN
$784.0M
24.3%
8.1%
8.8%
Becton, Dickinson and CompanyBDX
$711.0M
(39.7%)
(28.0%)
4.9%
ResMed Inc.RMD
$521.9M
148.3%
39.0%
20.7%
West Pharmaceutical Services, Inc.WST
$484.6M
(43.2%)
(14.0%)
2.0%
The Cooper Companies, Inc.COO
$107.6M
(10.9%)
3.9%
3.9%
Masimo CorporationMASI
$0.0
(100.0%)
(100.0%)
(100.0%)
ATR key stats
USD
Millions
Billions
Annual
Quarterly
Trailing
Key stats
Income statement
Balance sheet
Cash Flow Statement
Valuation
Ratios
Per share
Per employee
Dividends & Yields
| Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
% growth | 1,380.0 6.4% | 1,601.4 16.0% | 1,892.2 18.2% | 2,071.7 9.5% | 1,841.6 (11.1%) | 2,076.7 12.8% | 2,337.2 12.5% | 2,331.0 (0.3%) | 2,520.0 8.1% | 2,597.8 3.1% | 2,317.1 (10.8%) | 2,330.9 0.6% | 2,469.3 5.9% | 2,764.8 12.0% | 2,859.7 3.4% | 2,929.3 2.4% | 3,227.2 10.2% | 3,322.2 2.9% | 3,487.5 5.0% | 3,582.9 2.7% |
| Cost of Goods Sold (COGS) | 927.6 | 1,086.3 | 1,283.8 | 1,411.3 | 1,225.7 | 1,378.8 | 1,568.3 | 1,590.4 | 1,708.9 | 1,755.3 | 1,502.7 | 1,498.1 | 1,604.2 | 1,813.0 | 1,818.4 | 1,842.8 | 2,070.5 | 2,158.4 | 2,224.1 | 0.0 |
% margin | 452.4 32.8% | 515.1 32.2% | 608.4 32.2% | 660.4 31.9% | 615.9 33.4% | 697.9 33.6% | 768.9 32.9% | 740.7 31.8% | 811.1 32.2% | 842.5 32.4% | 814.5 35.2% | 832.9 35.7% | 865.1 35.0% | 951.8 34.4% | 1,041.3 36.4% | 1,086.5 37.1% | 1,156.7 35.8% | 1,163.8 35.0% | 1,263.4 36.2% | 3,582.9 100.0% |
| Operating Expenses | 302.6 | 353.5 | 397.7 | 432.0 | 417.6 | 429.8 | 481.9 | 478.7 | 514.7 | 536.1 | 490.4 | 522.4 | 541.4 | 601.7 | 649.2 | 720.5 | 786.1 | 778.0 | 852.5 | 3,086.4 |
| Research & Development Expenses (R&D) | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 65.4 | 71.8 | 76.2 | 67.1 | 66.2 | 68.2 | 75.3 | 82.8 | 92.5 | 551.2 | 544.3 | 92.8 | 582.2 |
| Selling, General & Administrative Expenses (SG&A) | 203.4 | 238.9 | 274.2 | 300.8 | 277.0 | 296.9 | 347.6 | 341.6 | 364.7 | 383.9 | 351.5 | 367.6 | 388.3 | 430.0 | 454.6 | 500.2 | 551.2 | 544.3 | 565.8 | 0.0 |
% margin | 149.8 10.9% | 161.6 10.1% | 210.7 11.1% | 228.4 11.0% | 205.9 11.2% | 268.1 12.9% | 287.0 12.3% | 258.9 11.1% | 284.6 11.3% | 306.4 11.8% | 324.1 14.0% | 310.5 13.3% | 321.5 13.0% | 286.3 10.4% | 371.7 13.0% | 339.5 11.6% | 347.3 10.8% | 379.3 11.4% | 404.0 11.6% | 496.5 13.9% |
| Interest Income | 0.0 | 0.0 | 8.9 | 13.1 | 3.3 | 3.2 | 5.7 | 3.0 | 3.2 | 4.8 | 5.6 | 2.6 | 5.5 | 7.1 | 4.2 | 1.0 | 3.7 | 2.7 | 4.4 | 12.1 |
| Interest Expense | 0.0 | 0.0 | 19.5 | 18.7 | 16.5 | 14.4 | 17.3 | 19.0 | 20.5 | 21.0 | 34.6 | 35.2 | 40.6 | 32.6 | 35.5 | 33.2 | 30.3 | 40.8 | 40.4 | 43.9 |
| Pre-tax Income | 142.0 | 148.3 | 200.0 | 221.0 | 184.1 | 254.4 | 274.9 | 241.4 | 264.4 | 286.3 | 294.6 | 280.5 | 294.8 | 266.0 | 342.1 | 301.2 | 321.7 | 334.7 | 374.8 | 469.8 |
% effective tax rate | 41.9 29.5% | 45.4 30.6% | 60.5 30.2% | 67.5 30.5% | 59.5 32.3% | 80.8 31.8% | 91.3 33.2% | 79.0 32.7% | 92.5 35.0% | 94.7 33.1% | 95.3 32.3% | 74.9 26.7% | 74.8 25.4% | 71.3 26.8% | 99.8 29.2% | 87.1 28.9% | 78.0 24.3% | 95.1 28.4% | 90.6 24.2% | 95.6 20.3% |
% margin | 100.0 7.2% | 102.9 6.4% | 141.7 7.5% | 153.5 7.4% | 124.6 6.8% | 173.5 8.4% | 183.7 7.9% | 162.6 7.0% | 172.0 6.8% | 191.7 7.4% | 199.3 8.6% | 205.6 8.8% | 220.0 8.9% | 194.7 7.0% | 242.2 8.5% | 214.0 7.3% | 244.1 7.6% | 239.3 7.2% | 284.5 8.2% | 374.5 10.5% |
| EPS | 1.42 | 1.48 | 2.06 | 2.26 | 1.84 | 2.58 | 2.76 | 2.45 | 2.60 | 2.95 | 3.19 | 3.27 | 3.52 | 3.12 | 3.81 | 3.32 | 3.72 | 3.66 | 4.34 | 5.65 |
| Diluted EPS | 1.39 | 1.44 | 1.98 | 2.18 | 1.79 | 2.48 | 2.65 | 2.38 | 2.52 | 2.85 | 3.09 | 3.17 | 3.41 | 3.00 | 3.66 | 3.21 | 3.60 | 3.59 | 4.25 | 5.53 |
% margin | 249.0 18.0% | 276.2 17.2% | 342.9 18.1% | 370.8 17.9% | 333.6 18.1% | 401.7 19.3% | 426.5 18.2% | 397.3 17.0% | 446.7 17.7% | 459.5 17.7% | 468.0 20.2% | 470.5 20.2% | 490.1 19.8% | 475.6 17.2% | 576.9 20.2% | 556.2 19.0% | 586.8 18.2% | 609.4 18.3% | 663.8 19.0% | 777.4 21.7% |
Discover more Stock Ideas
Undervalued stocks right now
Discover the top 20 best undervalued stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 32.1%
S&P Outperformance 19.1%
Next 3M Predicted Return 20.3%
Undervalued growth stocks
Discover the top 20 best undervalued large-cap growth stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 35.3%
S&P Outperformance 22.3%
Next 3M Predicted Return 26.8%
Undervalued dividend stocks
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Mar 2025.
3M Return 28.4%
S&P Outperformance 15.4%
Next 3M Predicted Return 16.9%
FAQ
1) What is AptarGroup, Inc.'s Cash & Cash Equivalents?
As of today, AptarGroup, Inc.'s last 12-month Cash & Cash Equivalents is $223.8M, based on the financial report for Dec 31, 2024 (Q4’2024).
2) What is AptarGroup, Inc.'s Cash & Cash Equivalents growth rate?
Over the last year, AptarGroup, Inc.'s Cash & Cash Equivalents growth was 0.1%. The average annual Cash & Cash Equivalents growth rates for AptarGroup, Inc. have been (8.4%) over the past three years, (1.5%) over the past five years.
3) Is AptarGroup, Inc.'s Cash & Cash Equivalents growth rate Good?
Over the last year, AptarGroup, Inc.'s Cash & Cash Equivalents growth was 0.1%, which is higher than industry growth of (0.4%). It indicates that AptarGroup, Inc.'s Cash & Cash Equivalents growth is Good.